Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Metreleptin

EU orphan designation number: EU/3/12/1022   
Active ingredient: Metreleptin
Indication: Treatment of Familial Partial Lipodystrophy
Sponsor: Aegerion Pharmaceuticals Limited
Lakeside House, 1 Furzeground Way, Stockley Park East, Uxbridge UB11 1BD, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/07/2012 Orphan designation EMA/OD/033/12 (2012)5144 of 17/07/2012
14/02/2014 Transfer of orphan designation EMA/OD/033/12/T/01 (2014)1032 of 12/02/2014
10/04/2014 Transfer of orphan designation EMA/OD/033/12/T/02 (2014)2519 of 08/04/2014
17/06/2014 Change of name and/or address of sponsor
27/03/2015 Transfer of orphan designation EMA/OD/033/12/T/03 (2015)2213 of 25/03/2015